Not Yet RecruitingPhase 2ACTRN12608000013369
Immune regulation and timing of chemotherapy in advanced/recurrent ovarian cancer to evaluate tumour response
Sponsor
Royal Women's Hospital
Enrollment
37 participants
Start Date
Mar 1, 2008
Study Type
Interventional
Conditions
Summary
We have shown that the immune system regulates itself on an approximately 2 week basis.By killing the inhibitory immune cells that prevent immune attack on the tumour using low dose oral chemotherapy it is hoped that tumour cells will die and responses achieved
Eligibility
Sex: FemalesMin Age: 21 Yearss
Inclusion Criteria2
- Rising CA125 (Rustin)
- previous lines of chemotherapy
Exclusion Criteria1
- Impending bowel obstruction
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Synchronised chemotherapy using cyclophosphamide 100 mg orally for 3 days each 2 week cycle for at least 3 cycles
Synchronised chemotherapy using cyclophosphamide 100 mg orally for 3 days each 2 week cycle for at least 3 cycles
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12608000013369
Related Trials
To Evaluate the Safety of Autologous Tumor-infiltrating Lymphocytes(TILs) for the Treatment of Recurrent Ovarian Cancer
NCT076511241 location
A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression
NCT0636585340 locations
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
NCT0356434052 locations
Efficacy and Safety of CapsuleX Combined With Cisplatin in Platinum-Resistant Recurrent Ovarian Cancer: A Single-Arm Prospective Clinical Study
NCT074953841 location
Combination Therapy for Recurrent Ovarian Cancer
NCT056107351 location